Immunoadjuvant Prednisolone Therapy for HIV-Associated Tuberculosis: A Phase 2 Clinical Trial in Uganda

Simple item page
dc.contributor.authorMayanja-Kizza, Harriet
dc.contributor.authorJones-Lopez, Edward
dc.contributor.authorOkwera, Alphonse
dc.contributor.authorWallis, Robert S.
dc.contributor.authorMugerwa, Roy D.
dc.contributor.authorUganda–Case Western Research Collaboration
dc.date.accessioned2022-05-20T05:41:46Z
dc.date.available2022-05-20T05:41:46Z
dc.date.issued2005
dc.description.abstractHuman immunodeficiency virus (HIV)–infected patients with tuberculosis (TB) respond to effective antituberculous therapy, but their prognosis remains poor. Mounting evidence from clinical studies supports the concept of copathogenesis in which immune activation that is triggered by TB and mediated by cytokines stimulates viral replication and worsens HIV infection, especially when immune function is preserved. We performed a phase 2, randomized, double-blind, placebo-controlled clinical trial in Kampala, Uganda, to determine whether immunoadjuvant prednisolone therapy in HIV-infected patients with TB who have CD4+ T cell counts ⩾200 cells/μL is safe and effective at increasing CD4+ T cell countsShort-term prednisolone therapy reduced levels of immune activation and tended to produce higher CD4+ T cell counts. Although prednisolone therapy was associated with a more rapid clearance of Mycobacterium tuberculosis from the sputum, it was also associated with a transient increase in HIV RNA levels, which receded when prednisolone therapy was discontinued. The intervention worsened underlying hypertension and caused fluid retention and hyperglycemiaThe benefits of prednisolone therapy on immune activation and CD4+ T cell counts do not outweigh the risks of adverse events in HIV-infected patients with TB and preserved immune functionen_US
dc.identifier.citationMayanja-Kizza, H., Jones-Lopez, E., Okwera, A., Wallis, R. S., Ellner, J. J., Mugerwa, R. D., & Uganda–Case Western Research Collaboration. (2005). Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. The Journal of infectious diseases, 191(6), 856-865.https://doi.org/10.1086/427995en_US
dc.identifier.issn1537-6613
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3273
dc.language.isoenen_US
dc.publisherThe Journal of infectious diseasesen_US
dc.subjectcytokinehivhypertensionimmunologic adjuvantsprednisolonesputumt-lymphocytestuberculosisugandatuberculosis and hivblood hiv rnahiv infectionsadverse eventen_US
dc.titleImmunoadjuvant Prednisolone Therapy for HIV-Associated Tuberculosis: A Phase 2 Clinical Trial in Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Immunoadjuvant Prednisolone Therapy for HIV-Associated Tuberculosis A Phase 2 Clinical Trial in Uganda.pdf
Size:
212.27 KB
Format:
Adobe Portable Document Format
Description:
Immunoadjuvant Prednisolone Therapy for HIV-Associated Tuberculosis: A Phase 2 Clinical Trial in Uganda
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences